Jump to ContentJump to Main Navigation

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Pasqualini, Jorge R.

Editorial Board Member: Fujimoto, Jiro / Groner, Bernd / Hubalek, Michael / Morfin, Robert / Saad, Farid / Schally, Andrew V. / Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Campagnoli, Carlo / Carruba, Giuseppe / Chen, Shiuan / Chetrite, Gerard / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Danza, Giovanna / Darbre, Philippa D. / Daxenbichler, Günter / Kloet, Ronald / Nicola, Alejandro F. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Flores-Morales, Amilcar / Garcia-Segura, Luis M. / Gee, J.M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Hilakivi-Clarke, Leena / Hampl, Richard / Iwase, Hirotaka / Jordan, V.Craig / Klocker, Helmut / Kurebayashi, Jyunichi / Labrie, Fernand / Luu-The, Van / Mendelson, Carole R. / Mück, Alfred O. / Nicholson, Robert / Norman, Anthony W. / O'Malley, Bert W. / Rafestin-Oblin, Marie-Edith / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Sanchez, Edwin R. / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Verhoeven, Guido / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Ylikomi, Timo / Yu, Qi

12 Issues per year

VolumeIssuePage

Issues

The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids

Michaela Dušková1 / Martin Hill1 / Luboslav Stárka1

1Institute of Endocrinology, CZ 11694 Prague 1, Czech Republic

Corresponding author: MUDr. Michaela Dušková, PhD, Institute of Endocrinology, Národní 8, 116 94 Praha 1, Czech Republic Phone: +420-224905280, Fax: +420 224905325,

Citation Information: Hormone Molecular Biology and Clinical Investigation. Volume 1, Issue 2, Pages 95–102, ISSN (Online) 1868-1891, ISSN (Print) 1868-1883, DOI: 10.1515/HMBCI.2010.010, September 2009

Publication History

Received:
2009-08-20
Accepted:
2009-08-28
Published Online:
2009-09-17

Abstract

Background: Finasteride is a 5α-reductase inhibitor that has received clinical approval for the treatment of human benign prostatic hyperplasia and androgenetic alopecia. The treatment is practically without side effects, although some occasional cases of depression syndrome have been reported. 5α-Reductase is an enzyme responsible for the reduction of testosterone, progesterone or deoxycorticosterone to their 5α-reduced derivatives possessing anticonvulsant, antidepressant, and anxiolytic activity. Therefore, the formation of GABAergic neuroactive steroids is likely to be impacted by finasteride.

Objective: The objective of the study was to show how the treatment of premature androgenetic alopecia with low doses (1 mg/day) of finasteride influences the broad spectrum of steroids with potential neuroactivity.

Methods: A group of 12 men with premature androgenetic alopecia participated in the present study. The steroid hormone profile was determined for all individuals. Finasteride was administered for 4 months at a daily dose of 1 mg. After the treatment, the same hormonal profile was determined again.

Results: 5α-Reduced steroids, e.g., 5α-dihydrotestosterone, androsterone, epiandrosterone, 5α-androstene-3α,17β-diol, allopregnanolone, isopregnaolone, and some 5-ene steroids, such as dehydroepiandrosterone and pregnenolone, decreased gradually during treatment.

Conclusions: The decrease of 5α-reduced steroids, especially of allopregnanediol, dihydrotestosterone, and pregnenolone, is probably one of the factors responsible for the increased occurrence of depression in men treated with finasteride, even at low doses.

Keywords: androgenetic alopecia; anxiety; depression; finasteride; neuroactive steroid; 5α-reductase

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.